Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Leading omni-direct lifestyle company Youngevity International, Inc. (NASDAQ: YGYI) is making enviable strides among several sectors of the direct selling industry as it expands its brands and offerings in multiple markets. Among the latest highlights is an expansion into the lucrative cruise line industry with the signing of a two-year contract to provide the company’s CLR Roasters coffee to over 60,000 crew members serving on 60 ships, along with passengers of three luxury cruise ships, a company press release states (http://nnw.fm/X3KMw).

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

• Health and Nutrition
• Home and Family
• Food and Beverage
• Spa and Beauty
• Fashion
• Essential Oils
• Photo and scrapbooking
• Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $5.89, up 35.40%, on 600,054 volume with 2,415 trades. The average volume for the last 3 months is 21,865 and the stock's 52-week low/high is $3.1674/$5.50.

Recent News

• Youngevity International, Inc. (NASDAQ: YGYI) Coffee Business Takes to the High Seas, Boosts Profits
• YGYI's CLR Roasters Further Expands Foot Print in Cruise Line Industry
• Youngevity CEO, Steve Wallach, Appointed To Direct Selling Association Board Of Directors

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields; medical devices; and research and development, announces the commencement of a direct response television (DRTV) media campaign with mega-entrepreneur Kevin Harrington’s award-winning As Seen On TV production company.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

• Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
• Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
• KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.22, up 22.00%, on 188,914 volume with 260 trades. The average volume for the last 3 months is 21,320 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

• Earth Science Tech, Inc. (ETST) Commences DRTV Media Campaign with Former ‘Shark Tank’ Star Kevin Harrington’s Award-Winning As Seen On TV Production Company
• CannabisNewsAudio Announces Audio Press Release (APR) on Earth Science Tech Inc. (OTCQB: ETST) Seizing Immense Opportunity with CBD-Based Pharmaceuticals, Supplements
• CannabisNewsWire Announces Publication on Superior Hemp-Derived, CBD Formulations Ready for Global Recognition in Nutraceutical, Pharmaceutical Sectors

NUGL Inc. (NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (NUGL) (the “Company”), is bringing the cannabis industry to the 21st century. The company’s Technical Engineer of software programming, C.J. Melone, talked with “Stock Day” host Everett Jolly about the growth potential and challenges for the market. Also today, CannabisNewsWire released a report highlighting how the company is helping to offset synthetic marijuana overdoses by making the real thing more affordable for people with limited means.

NUGL Inc. (NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.78, up 6.59%, on 349,460 volume with 323 trades. The average volume for the last 3 months is 139,683 and the stock's 52-week low/high is $0.405/$1.79.

Recent News

• NUGL Inc. is on The Forefront of the Cannabis Industry and Tells Uptick Newswire Stock Day Podcast It Only Gets Better from Here
• 420 with CNW – Washington D.C. Sees Spike of Synthetic Marijuana Overdoses
• NUGL Inc. (NUGL) Platform Offering Enhanced Customer Services by Allowing Searches for Cannabis Brands by Name

Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

Vancouver-based junior exploration company Marifil Mines (TSX.V: MFM) (OTCQB: MFMLF) holds lithium interests in Catamarca province, in the same geologic and mining region that hosts FMC’s world-renowned Hombre Muerto mine. To view the full article, visit: http://nnw.fm/6IhlJ.

Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.0879, off by 5.28%, on 51,792 volume with 12 trades. The average volume for the last 3 months is 19,205 and the stock's 52-week low/high is $0.009/$0.165.

Recent News

• NetworkNewsBreaks – Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) Exploring in an Inviting Regulatory Environment for Investors
• Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) Augments Prospectiveness of San Roque Zones with Core Assay Report
• Marifil Mines Ltd.’s (TSX.V: MFM) (OTCQB: MFMLF) Lithium Exploration in Argentina is No Cause for Tears

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' or the ''Company''), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced that its ultra high pressure product line of instruments, methods, and technology platforms was prominently featured at the recent Institute of Food Technologists (''IFT'') annual meeting in Chicago, IL.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.70, up 5.71%, on 2,369 volume with 7 trades. The average volume for the last 3 months is 1,743 and the stock's 52-week low/high is $2.70/$5.00.

Recent News

• Pressure BioSciences' Ultra High Pressure Instruments, Processing Methods, and Platform Technologies Prominently Featured at Leading Food Science Meeting
• Pressure BioSciences Announces Commercial Release of the HUB880 Explorer
• Pressure BioSciences Inc.’s (PBIO) Invention for “Hands-Free” High-Pressure Technology Sample Prep Workflow Platform Earns Key US Patent

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

NetworkNewsAudio announces the Audio Press Release (APR) titled “New Automakers Emerge as Electric Vehicle Revolution Rages On,” featuring Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF). To hear the NetworkNewsAudio version, visit: http://nnw.fm/0QCec. To read the full editorial, visit: http://nnw.fm/i7eRr.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $1.18, up 0.86%, on 89,561 volume with 77 trades. The average volume for the last 3 months is 36,579 and the stock's 52-week low/high is $0.604/$2.23.

Recent News

• NetworkNewsAudio Announces Audio Press Release (APR) on Standard Lithium Ltd. Leveraging “Moneyball” Approach to Create Fast-Track to Production
• NetworkNewsWire Announces Publication on Automotive Market Evolution May Fuel Strong Demand for Lithium
• New Automakers Emerge as Electric Vehicle Revolution Rages On

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Marijuana Company of America Inc. (OTC: MCOA), a client of CNW that focuses on product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMART™”, an affiliate marketing program to promote and sell its products, as well as leasing of real property and expansion of business into ancillary areas of the legalized cannabis and hemp industry. To view the full publication, titled “Canadian Cannabis Legalization Set to Transform the Industrial Hemp Industry,” visit: http://cnw.fm/9ejN3. Also today, the company was highlighted in a report discussing how Personal Care and Healthcare products infused with cannabidiol (CBD) are rapidly becoming the product du jour. Additionally, MCOA was mentioned as one of the companies helping to offset the rise in synthetic marijuana overdoses.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0281, up 1.08%, on 9,542,902 volume with 525 trades. The average volume for the last 3 months is 8,101,290 and the stock's 52-week low/high is $0.0219/$0.0728.

Recent News

• CannabisNewsWire Announces Budding Opportunity for Cannabis Companies and Hemp Growers with Canada’s Widening Legalization
• Cannabidiol (CBD) Infused Personal Care Products Industry Becoming More Mainstream with More Consumers
• 420 with CNW – Washington D.C. Sees Spike of Synthetic Marijuana Overdoses

DeepMarkit Inc. (TSX-V: MKT) (OTC: MKTDF)

The QualityStocks Daily Newsletter would like to spotlight DeepMarkit Inc. (MKTDF).

In the 19th century, the maxim “build a better mousetrap, and the world will beat a path to your door” might have applied, but that was like… two hundred years ago, when consumer choices were rather limited and there was no internet. Marketplaces today are fiercely competitive, and the business that eschews marketing probably won’t survive for very long. Particularly online, marketing tools, like those provided by DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF), are crucial to attracting customers and converting their visits into sales.

DeepMarkit Inc. (TSX-V: MKT) (OTC: MKTDF), based in Calgary, Alberta, Canada, is a patent pending gamification technology company inventing new ways to engage consumers and other audiences. The Company’s proprietary promotions platform – “Gamify” – enables businesses and agencies to create branded games that incentivize consumers, thus driving sales, capturing data and generating leads. The DeepMarkit platform integrates next-gen gamification engagement mechanics with interactive advertising industry standards and powerful visuals, including 3-D images. Customers may choose from both free and paid solutions suitable for campaigns of all sizes, targeting multiple channels on the web, mobile and social media.

A team of seasoned, passionate gaming executives, led by president and CEO Darold Parken, has worked together for more than 15 years developing games and gaming systems that are still used today by some of the largest gaming companies in the world. This accomplished executive team founded Chartwell Technologies, acquired in 2011 by Amaya Gaming, which now is known as The Stars Group (Nasdaq: TSG) with a market cap of over $5 billion.

Gamify offers a selection of easily customizable gaming apps featuring a customer’s branded e-store in addition to tailored landing pages, technical support, real-time analytics, data collection and an engaging marketing campaign. Gamify’s patent-pending app comes complete with unique user incentives that draw consumers in with games and prizes, which in turn engages shoppers, turning them into buyers and building brand loyalty.

The gamification market is rapidly expanding and projected to be worth $22 billion by 2022, with a CAGR of 41 percent. DeepMarkit is the only publicly listed company focused solely on this exploding market that embraces any size of business, from the mom-and-pop shops to the blue-chip giants. DeepMarkit’s management team knows that increasing a customer’s conversion rate by a mere 1 percent has the potential to double revenue, which is why Gamify’s app and its ability to transform simple shoppers into engaged buyers is so compelling.

“Our marketing platform enables customers to build branded games that incentivize audiences, generate leads, and drive sales. Businesses need a way to stand out from the crowd,” Parken states in an investor’s video (https://www.youtube.com/watch?v=97hJoRKR92k). “DeepMarkit’s gamification platform gives customers that way to stand out and it’s a way that they can afford. That’s the strength of our platform. For a relatively small amount of money, any business can create a very powerful, high quality customer engagement using gamification.”

DeepMarkit recently entered into a joint marketing agreement with ITN International (“ITN”), a global leader in trade show data capture and analytics. The agreement will enable the 1.5 million exhibitors at the 125-plus yearly events serviced by ITN to purchase a customizable campaign with prize delivery and branded games that can be used in collaboration with ITN’s lead retrieval solutions. DeepMarkit and ITN are currently integrating DeepMarkit’s patent-pending gamification platform directly into ITN’s exhibitor portal.

“We started DeepMarkit because we have a passion for games and we believe in the power of games, not just for entertainment but more importantly as a tool for business,” Parken said. “DeepMarkit is a gamification company. What we mean by that is that we create innovative ways to use games for business purposes. Games to generate customer leads, games to promote products, deliver rewards, build brand awareness and customer loyalty.”

Selected as the winner of the New Company/Product pitch competition at the Retail Global 2017 Conference held in Las Vegas, Gamify’s platform has also attracted a $1.5 million investment from Allstate International LLC in Hong Kong. The investment gives Allstate a 10 percent stake in DeepMarkit and a great opportunity to bring the Gamify platform into the burgeoning Asian gaming market.

DeepMarkit Inc. (MKTDF), closed the day's trading session at $0.0206, up 1.48%, on 100,000 volume with 2 trades. The average volume for the last 3 months is 24,020 and the stock's 52-week low/high is $0.0195/$0.1199.

Recent News

• DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) “Gamify” Platform Proves its Worth with Positive Feedback
• NetworkNewsBreaks – DeepMarkit Corp. (TSX-V: MKT) (OTCQB: MKTDF) Platform Delivering High Conversion Rates
• DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) Sees Passion for Gaming in Asia-Pacific Market as Major Opportunity for Global Gamification Strategy

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTC: SGMD), one of the largest publicly traded hydroponics supply companies, today made comments on its recent investment into the industrial hemp market and on the pending Hemp Bill of 2018, which now appears to be on the verge of passage and enactment into federal law. Also today, it was announced that independent research firm SeeThruEquity has commenced coverage of Sugarmade. In its initial report, SeeThruEquity (http://nnw.fm/OKx4R) noted, “Sugarmade appears well-positioned to target the large and growing opportunity to supply hydroponics equipment and supplies to the cannabis cultivation market in the United States through its master marketing agreement with BizRight.”

Sugarmade, Inc. (SGMD) one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.1089, up 3.42%, on 2,175,022 volume with 235 trades. The average volume for the last 3 months is 1,291,046 and the stock's 52-week low/high is $0.028/$0.43.

Recent News

• Sugarmade Comments on its Hemp Investment, the $22 Billion Hemp-Derived CBD Market, and Pending Hemp Bill Passage
• Research Firm SeeThruEquity Begins Coverage of Hydroponics Supply Provider Sugarmade, Inc. (SGMD)
• NetworkNewsBreaks – Sugarmade, Inc. (SGMD) Strategic Investment Offers Great Opportunity in the Cannabis Sector

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC: NUGS) and True Promise Beauty announce the development of LYXR, a new line of cannabidiol (CBD)-based luxury skin, hair and body products. LYXR products are developed from a line of hemp-derived phytocannabinoids and other natural ingredients that provide high-performing skin, hair and body topical solutions.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $4.1015, off by 3.27%, on 96,699 volume with 269 trades. The average volume for the last 3 months is 98,528 and the stock's 52-week low/high is $0.0309/$7.13.

Recent News

• Cannabis Strategic Ventures and True Promise Beauty Elevate Personal Care Product Industry With LYXR, a Line of CBD-Based Skin, Hair and Body Products
• NetworkNewsBreaks – Cannabis Strategic Ventures, Inc. (NUGS) Expands Diverse Portfolio, Enters Pet Care Market
• Cannabis Strategic Ventures, Inc. (NUGS) Fine-tunes Foray into Cannabis Space with Brand Specific Strategies, Acquisitions

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that management will present at two upcoming investment conferences:

• Fourth Annual Robins Equity Research Roundup on Tuesday, September 25, at 10:00 a.m. Pacific time, in Portland, Oregon; and

• The MicroCap Conference on Monday, October 1, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) at the Essex House in New York City.

A live webcast and replay of the presentation at The MicroCap Conference will be available on the Investors section of the Company’s website, http://ir.cytodyn.com/, prior to the presentation date.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.604, off by 2.58%, on 169,966 volume with 62 trades. The average volume for the last 3 months is 366,362 and the stock's 52-week low/high is $0.0099/$0.50.

Recent News

• CytoDyn to Present at Two Upcoming Conferences
• NetworkNewsBreaks – CytoDyn Inc. (CYDY) Highlighted in Corporate Summary from Leading Small Cap Media Portal
• CytoDyn to Hold Investment Community Conference Call on September 13, 2018

Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF)

The QualityStocks Daily Newsletter would like to spotlight Phivida Holdings Inc. (PHVAF).

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF), a food and beverage company that produces hemp-infused products, has announced the launch of a new line of drinks and supplements featuring hemp extracts into the mainstream market. According to a company press release (http://nnw.fm/c3S5b), the Oki line of products, which includes food supplements and flavored functional beverages containing active hemp extracts, is to be available in up to 2,400 retail outlets across the United States.

Headquartered in Vancouver, Canada, with operations offices in southern California, Phivida Holdings Inc. (CSE: VIDA) (OTC: PHVAF) is a premium food and beverage company that develops CBD-infused functional foods, beverages and supplements poised for global distribution. All products in the Phivida label are infused with organic, hemp-derived cannabinoids into a variety of premium foods, beverages and clinical products for everyday health. Phivida is guided by a team of Fortune 500-caliber executives focused on a new strategic portfolio of products and brands, comprehensive consumer research, new product and brand development, improved visual identity and packaging design, and a strong distribution strategy.

The company’s motto – “Celebrating Health and Wellness, in Harmony™” – underscores Phivida’s mission to lead the alternative health care sector as the benchmark standard in premium CBD-infused functional beverages and tinctures. To execute this goal, Phivida is taking advantage of positive legislative developments in the United States and has defined an elevated national route-to-market strategy across the U.S. where small regional distributors will be now be replaced with large national distributors.

Management

Phivida’s management team includes president and CEO Jim Bailey, former president of Red Bull Canada and global chief marketing officer for Merrell Outdoors; Chief Marketing Officer Michael Cornwell, former chief marketing officer for Samsung New Zealand and the former director of marketing for Red Bull Canada; and Doug Campbell, former director of sales for Red Bull North America, who as Phivida’s chief commercial officer is tasked with driving new sales revenue growth.

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF), the company’s strong balance sheet carries CAD$15.7 million with no debt or loans with less than 60 million shares outstanding and the company is now well-capitalized to fun major mainstream distribution with a solid structure poised for long-term growth.

The Science

Using encapsulation technology, Phivida uses full spectrum CBD-hemp oil (rich in naturally occurring phytocannabinoids) converted into a water-soluble delivery format, which enhances delivery and absorption of the cannabinoids into the human body – up to an estimated tenfold.

Encapsulated CBD is infused into functional beverages, food and supplements containing a proprietary blend of phytonutraceuticals studied to target a range of health and wellness conditions. Phivida tests every product for microbials, heavy metals, pesticides, residual solvents, terpenes, and potency to guarantee less than 0.3 percent THC (tetrahydrocannabinol, the chemical compound in cannabis responsible for a euphoric high) is present.

Regulations

Federally legal under the 2014 Farm Bill, CBD from Hemp Oil is a rapid growth market across the USA. When derived from marijuana, CBD remains a schedule one controlled substances, giving hemp derived CBD oil infused products a competitive advantage on regulations. On June 28, 2018, the U.S. Senate passed the Agriculture Improvement Act of 2018 (i.e. the “Farm Bill), lifting the USA Industrial Hemp laws to an agricultural commodity status and effectively removed hemp from the controlled substance list.

Earlier this year, another milestone court ruling also provided significant regulatory support for the US CBD-Hemp sector. In February 2018, the Supreme Court preceded over the HIA (Hemp Industry Association) vs. DEA (Drug Enforcement Agency) in a class-action suit concerning the issue of CBD extracted from hemp, and the legality of industrial hemp. In the final ruling the Supreme Court unequivocally determined that – when produced domestically under the Farm Bill – hemp (and its derivatives) are not a controlled substance.

The Supreme Court ruling also found the Farm Bill (as it relates to hemp) “pre-empts” the Controlled Substances Act. Congress has since exempted Farm Bill hemp from the Controlled Substances Act (CSA) giving the Farm Bill primary jurisdiction over the governance of the CBD-Hemp Oil industry in the USA.

The DEA further conceded it does not “seek to control cannabinoids,” and that only marijuana derived cannabinoids are governed under the Controlled Substances Act. In May of 2018, the DEA issued a formal directive to all federal agencies (e.g. US Customs and Border Patrol) stating that cannabinoids are not controlled substances unless derived from marijuana, and that the “mere presence of cannabinoids” in any product or derivative does not render it a controlled substance. The Supreme Court ruling also resulted in the mediation of a settlement in what is now the third successful HIA vs. DEA suit in over a decade.

In Canada, the Senate approval of Bill C-45 legalized the production, distribution and use of recreation cannabis – with edibles to be added in 2019. The bill will officially become law as of October 17, 2018, creating a legal framework for the production, distribution, sale and possession of cannabis across Canada including cannabinoid-infused beverages.

3 Wholly Owned Subsidiaries

• Phivida Organics Inc. offers professional-grade, wholesale, whole plant hemp oil extracts made from 100-percent certified organic hemp stalk. Phivida’s hemp oil extracts are CO2-extracted under quality assurance/clinical standards and are third-party lab tested to assure only pharmaceutical grade, cGMP certified, full-spectrum products are produced and available for sale. Phivida Organics produces hemp oil extracts that deliver nano-encapsulated cannabinoids in water soluble formulations designed to be absorbed up to 10 times faster than other oils, providing up to 400 percent bioavailability. Phivida Hemp Oil Vida+ extract products are available now online at www.Phivida.com.
• Phivida Nutrition blends the best of nature into CBD-infused lifestyle branded beverages including a variety of CBD infused iced teas and CBD infused flavored waters.
• Phivida Enhanced – Under the VIDA brand, CBD-infused tinctures, capsules and other supplement products are distributed to alternative health care clinics across the USA.

WeedMD-Phivida

Phivida has signed a binding letter of intent to joint venture WeedMD Inc. (TSX-V: WMD) (OTC:WDDMF) (FSE:4WE), a Health Canada federally licensed producer and distributor of medical cannabis, to form a joint venture focused on cannabis-infused beverages. The new joint-venture company, Cannabis Beverages Inc. (“CanBev”), plans to develop a production facility at WeedMD’s state-of-the-art greenhouse facility in Strathroy, Ontario, Canada. CanBev is on track to build and operate the first cannabis-infused beverage production facilities in Canada. The joint venture will focus on manufacturing, marketing and distribution of cannabinoid-infused beverages for the legalized medical and adult-use cannabis markets.

Management from both WeedMD and Phivida are collaborating on design and engineering strategies and site evaluations on a 610,000-square-foot, state-of-the art facility in Strathroy for the development of CanBev. As an emerging certified food grade production plant, the Strathroy facility is an ideal location and comes is equipped with extensive production infrastructure, including 50,000 sq. ft. of food production and packaging area, cold storage, loading docks, and adequate space to expand for future growth.

Strategic Agreements

Phivida Organics has also entered into an agreement to carry out a pharmacokinetic (PK) study on its hemp-derived, nanoencapsulated CBD with Artelo Biosciences Inc. at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England. The study will test encapsulated-CBD on healthy volunteers and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations developed by Phivida Organics.

Phivida has also activated distribution agreements with Asayake Inc. to become one of the first federally approved CBD-infused food and supplement brands in Japan. With first mover status achieved, Phivida now markets to an underserved, yet highly informed population of 127 million patients and practitioners. The supplement market in Japan is estimated at US$10 billion with the overall functional foods market at US$21 billion. The Asia-Pacific region is the fastest growing market for natural plant-based supplements. Phivida now plans to prepare a formal application to Japan’s Consumer Affairs Agency to register the company’s CBD-infused functional food and beverage products for approval under the country’s Food with Functional Claims regime. The functional beverage market in Japan is estimated at US$10.35 billion with a CAGR of 2.5 percent (2015-2025).

Further Information

www.Phivida.com
+1 (844) 744-6646 (ext. #2)
IR@Phivida.com

Phivida Holdings Inc. (PHVAF), closed the day's trading session at $0.9242, off by 3.43%, on 150,203 volume with 98 trades. The average volume for the last 3 months is 79,057 and the stock's 52-week low/high is $0.05/$1.80.

Recent News

• Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Launches Mass Market Hemp-Infused Beverages and Supplements
• NetworkNewsBreaks – Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) Has Achieved DTC, CNS Eligibility to Simplify Settlement, Boost Liquidity
• Phivida introduces premium active hemp extract infused functional beverage and supplement line to mainstream retailers in the U.S.